BlackRock Health Sciences Trust
Explore BlackRock Health Sciences Trust stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
BME — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
- Meaningful dividend yield is available.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BlackRock, Inc. | $995.6 | 25.92 | $162.12 B | 2.24% | 4.7% | 11.52% | $1,219.94 / $917.39 | $360.41 |
| 2. | Blackstone Inc. | $115.35 | 46.14 | $140.9 B | 4% | — | 36.16% | $190.09 / $101.73 | $11.57 |
| 3. | Brookfield Corporation | $44.6 | 74.29 | $99.25 B | 0.01% | 4.08% | 2.84% | $49.57 / $37.93 | $21.33 |
| 4. | KKR & Co. Inc. | $93.4 | 28.32 | $83.86 B | 0.82% | 0.14% | 9.92% | $153.87 / $82.67 | $34.67 |
| 5. | Apollo Global Management, Inc. | $128.03 | 64.52 | $73.81 B | 1.75% | 6.4% | 5.34% | $157.28 / $99.56 | $40.31 |
| 6. | Brookfield Asset Management Ltd. | $46.18 | 29.25 | $73.74 B | 4.3% | 20.18% | 26.36% | $64.1 / $42.2 | $6.29 |
| 7. | State Street Corporation | $161.75 | 14.66 | $44.94 B | 2.06% | — | 11.09% | $163.95 / $95.62 | $99.76 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 77.54 M | 24.07 M | 20.41 M | -25.97 M |
| Operating Profit | — | — | — | — |
| Net Profit | 76.97 M | 23.45 M | 20.02 M | -26.47 M |
| EPS in Rs | 5.96 | 1.81 | 1.55 | -2.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 570.14 M | 550.38 M | 596.1 M | 606.13 M |
| Total Liabilities | 1.83 M | 4.24 M | 7.97 M | 5.93 M |
| Equity | 568.3 M | 546.14 M | 588.14 M | 600.2 M |
| Current Assets | — | — | — | — |
| Current Liabilities | — | — | — | — |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 54.58 M | 65.52 M | 32.02 M | -0.87 M |
| Investing CF | — | — | — | — |
| Financing CF | -54.59 M | -65.52 M | -32.02 M | 0.88 M |
| Free CF | 54.58 M | 65.52 M | 32.02 M | -0.87 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 17.94% | 178.59% | — | — |
| Earnings Growth % | 17.17% | 175.62% | — | — |
| Profit Margin % | 97.44% | 98.07% | 101.93% | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-04-15 | $0.262 |
| 2026-03-13 | $0.262 |
| 2026-02-13 | $0.262 |
| 2026-01-20 | $0.262 |
| 2025-12-22 | $0.262 |
Stock Splits
No stock split history available.
Frequently Asked Questions — BlackRock Health Sciences Trust
Will BlackRock Health Sciences Trust stock hit $48 in 2026?
BlackRock Health Sciences Trust (BME) is currently trading at $39.94, with a 52-week range of $35.03 to $42.74. Reaching the $48 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Whether BlackRock Health Sciences Trust can reach $48 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Financial Services space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, BME has delivered a 2.5% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the BME Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is BlackRock Health Sciences Trust stock worth buying at $39.94?
Whether BlackRock Health Sciences Trust (BME) is worth buying at $39.94 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: BlackRock Health Sciences Trust trades at a Price-to-Earnings (P/E) ratio of 6.8x, which can be compared against other Financial Services companies to assess whether the stock is expensive or attractively priced relative to its peers.
Profitability & efficiency: Its Return on Equity (ROE) stands at 14.4%.
Financial health: The Debt-to-Equity ratio of 0.16 indicates a conservative balance sheet with more equity than debt, reducing financial risk.
Analyst view: Analyst estimates are not currently available for BME. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for BlackRock Health Sciences Trust (BME) in 2026?
Analyst price target data for BlackRock Health Sciences Trust (BME) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore BME's financial ratios, historical returns, and fundamental data available on this page to form your own view.
Is BlackRock Health Sciences Trust overvalued at a P/E ratio of 6.8x?
BlackRock Health Sciences Trust (BME) currently has a Price-to-Earnings (P/E) ratio of 6.8x, meaning investors are paying $6.8 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:
Sector context: The Financial Services sector tends to command higher valuation multiples when growth expectations are elevated. A 6.8x P/E is relatively low, which could indicate an undervalued opportunity — or it may reflect lower expected growth or higher perceived risk.
Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation.
Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of BME's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.
How much can you earn by reinvesting BlackRock Health Sciences Trust dividends?
Dividend reinvestment — commonly known as DRIP (Dividend Reinvestment Plan) — is a powerful wealth-building strategy where instead of receiving your dividend payouts as cash, the dividends are automatically used to purchase additional shares of BlackRock Health Sciences Trust (BME). Over time, this creates a compounding effect: more shares generate more dividends, which buy even more shares.
BlackRock Health Sciences Trust currently offers a dividend yield of approximately 779.00%. While this may seem modest in isolation, the real power of DRIP emerges over long holding periods. An investor who reinvested dividends consistently over 10–20 years would accumulate significantly more shares than one who took dividends as cash — and those extra shares continue generating their own dividend income.
The key variables that determine your DRIP returns are: your initial investment amount, the number of years you stay invested, the dividend yield at the time of each reinvestment, and whether BlackRock Health Sciences Trust grows or cuts its dividend over time. Market price appreciation of BME also plays a significant role — rising share prices increase the value of your accumulated shares.
Use the BME DRIP Calculator on StockSifting to enter your investment amount, start date, and contribution frequency — and see a year-by-year breakdown of shares accumulated, dividends earned, and total portfolio value. Past dividend payments are not a guarantee of future payouts. This is not financial advice.